Clinical Trials Directory

Trials / Conditions / Recurrent Extrahepatic Bile Duct Cancer

Recurrent Extrahepatic Bile Duct Cancer

18 registered clinical trials studyying Recurrent Extrahepatic Bile Duct Cancer.

StatusTrialSponsorPhase
CompletedPET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Ca
NCT02088775
Fox Chase Cancer CenterN/A
CompletedCPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
NCT01766219
Wake Forest University Health SciencesPhase 1 / Phase 2
WithdrawnSelumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duc
NCT01859182
National Cancer Institute (NCI)Phase 2
TerminatedCediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers
NCT01229111
National Cancer Institute (NCI)Phase 2
CompletedSelumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery
NCT00553332
National Cancer Institute (NCI)Phase 2
TerminatedTrastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer Th
NCT00478140
National Cancer Institute (NCI)Phase 2
CompletedErlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Nec
NCT00397384
National Cancer Institute (NCI)Phase 1
CompletedBevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors
NCT00356889
National Cancer Institute (NCI)Phase 2
CompletedLapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
NCT00107536
National Cancer Institute (NCI)Phase 2
CompletedS0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma
NCT00238212
National Cancer Institute (NCI)Phase 2
CompletedLapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot B
NCT00101036
National Cancer Institute (NCI)Phase 2
TerminatedEF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
NCT00087191
National Cancer Institute (NCI)N/A
TerminatedBortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Du
NCT00085410
National Cancer Institute (NCI)Phase 2
CompletedErlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
NCT00033462
National Cancer Institute (NCI)Phase 2
Completed7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid
NCT00031681
National Cancer Institute (NCI)Phase 1
TerminatedBMS-247550 in Treating Patients With Liver or Gallbladder Cancer
NCT00023946
National Cancer Institute (NCI)Phase 2
CompletedInterleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
NCT00004074
National Cancer Institute (NCI)Phase 1
WithdrawnStent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating
NCT00253617
Jonsson Comprehensive Cancer CenterPhase 3